Clarity Pharmaceuticals Ltd (CU6) is a clinical stage radiopharmaceutical company. The company is a global leader in Targeted Copper Theranostics (TCT), developed with their proprietary SAR Technology platform. The group also has a range of products in clinical trials which address both prostate cancer and breast cancer as well as neuroendocrine tumours (NETs) and neuroblastoma of cancer.
Clarity Pharmaceuticals
Follow
Get notifications in MyBN when activity occurs.
Company Activity
NEW ROLE: Michelle Parker, Chief Clinical Officer | 24 Sep 2024 | |
NEW ROLE: Robert Thomas, Non-Executive Director | 07 Apr 2022 | |
NEW ROLE: Rosanne E Robinson, Lead Independent Director, Non-Executive Director | 07 Apr 2022 | |
NEW ROLE: Alan J Taylor, Executive Chairman, Executive Director | 07 Apr 2022 | |
NEW ROLE: Charles G O'Bryan-Tear, Non-Executive Director | 07 Apr 2022 | |
NEW ROLE: Colin D Biggin, Chief Executive Officer, Managing Director | 07 Apr 2022 | |
NEW ROLE: Thomas Ramdahl, Non-Executive Director | 07 Apr 2022 | |
NEW ROLE: Robert C Vickery, Chief Financial Officer, Company Secretary | 07 Apr 2022 | |
NEW ROLE: Christopher Roberts, Non-Executive Director | 07 Apr 2022 |